{"id": "399873", "url": "https://fevir.net/resources/Composition/399873", "date": "2025-12-11T20:35:21.032Z", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"], "versionId": "5", "lastUpdated": "2025-12-11T20:35:21.032Z"}, "type": {"text": "Outcome Measure Report", "coding": [{"code": "OutcomeMeasureReport", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "OutcomeMeasureReport"}]}, "title": "Outcome Measures Report for NCT03421379", "author": [{"display": "[No author listed.]"}], "status": "final", "custodian": {"type": "Organization", "display": "Computable Publishing LLC", "reference": "Organization/118079"}, "relatesTo": [{"type": "cite-as", "targetMarkdown": "Outcome Measures Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399873. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399873. Computable resource at: https://fevir.net/resources/Composition/399873#json."}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "399873", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-outcome-measure-report", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Composition", "section": [{"focus": {"type": "EvidenceVariable", "display": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267226", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-primaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participant who completed both treatment visits and had evaluable treatment success data.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose up to 30 minutes post each glucagon administration</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>", "status": "generated"}, "entry": [{"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}], "title": "Glucagon Nasal Powder"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>", "status": "generated"}, "entry": [{"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}], "title": "Glucagon Hydrochloride Solution"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379", "reference": "Evidence/267232", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-primaryOutcomeMeasure-0--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379", "reference": "Evidence/267233", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-primaryOutcomeMeasure-0--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379", "reference": "Evidence/267244", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-primaryOutcomeMeasure-0-OutcomeAnalysis-0-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267226", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-primaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267227", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized patients who receive at least 1 dose of the study drug and have evaluable PD data.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>", "status": "generated"}, "entry": [{"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}], "title": "Glucagon Nasal Powder"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>", "status": "generated"}, "entry": [{"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}], "title": "Glucagon Hydrochloride Solution"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379", "reference": "Evidence/267234", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcomeMeasure-0--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379", "reference": "Evidence/267235", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcomeMeasure-0--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267227", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267228", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PD data.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>", "status": "generated"}, "entry": [{"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}], "title": "Glucagon Nasal Powder"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>", "status": "generated"}, "entry": [{"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}], "title": "Glucagon Hydrochloride Solution"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379", "reference": "Evidence/267236", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcomeMeasure-1--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379", "reference": "Evidence/267237", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcomeMeasure-1--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267228", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267229", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-2", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>", "status": "generated"}, "entry": [{"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}], "title": "Glucagon Nasal Powder"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>", "status": "generated"}, "entry": [{"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}], "title": "Glucagon Hydrochloride Solution"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379", "reference": "Evidence/267238", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcomeMeasure-2--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379", "reference": "Evidence/267239", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcomeMeasure-2--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267229", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-2", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267230", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-3", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>", "status": "generated"}, "entry": [{"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}], "title": "Glucagon Nasal Powder"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>", "status": "generated"}, "entry": [{"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}], "title": "Glucagon Hydrochloride Solution"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379", "reference": "Evidence/267240", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcomeMeasure-3--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379", "reference": "Evidence/267241", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcomeMeasure-3--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267230", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-3", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267231", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-4", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>", "status": "generated"}, "entry": [{"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}], "title": "Glucagon Nasal Powder"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>", "status": "generated"}, "entry": [{"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}], "title": "Glucagon Hydrochloride Solution"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379", "reference": "Evidence/267242", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcomeMeasure-4--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379", "reference": "Evidence/267243", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcomeMeasure-4--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267231", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-4", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"}]}]}]}